Tekla Capital Management LLC Crinetics Pharmaceuticals, Inc. Call Options Transaction History
Tekla Capital Management LLC
- $2.53 Billion
- Q2 2023
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CRNX
# of Institutions
220Shares Held
75.8MCall Options Held
631KPut Options Held
749K-
Black Rock Inc. New York, NY5.44MShares$250 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL5.23MShares$241 Million2.68% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct4.95MShares$228 Million0.59% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA4.16MShares$191 Million5.55% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.82MShares$176 Million0.02% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $2.48B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...